Carolin Prexler

Munich, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo.

Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo.

Journal: Leukemia
Published: July 05, 2024

Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas.

Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas.

Journal: Frontiers in immunology
Published: November 30, 2023

TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.

TCR-transgenic T cells and YB-1-based oncolytic virotherapy improve survival in a preclinical Ewing sarcoma xenograft mouse model.

Journal: Frontiers in immunology
Published: October 31, 2023

Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma.

Correlation of Transcriptomics and FDG-PET SUVmax Indicates Reciprocal Expression of Stemness-Related Transcription Factor and Neuropeptide Signaling Pathways in Glucose Metabolism of Ewing Sarcoma.

Journal: Cancers
Published: October 18, 2022

No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy.

No Improvement of Survival for Alveolar Rhabdomyosarcoma Patients After HLA-Matched Versus -Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Compared to Standard-of-Care Therapy.

Journal: Frontiers in oncology
Published: February 17, 2022

Correction to: Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis.

Correction to: Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis.

Journal: Journal of experimental & clinical cancer research : CR
Published: January 04, 2022

Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing's Sarcoma, Enhancing T Cell Cytotoxicity.

Monocyte Maturation Mediators Upregulate CD83, ICAM-1 and MHC Class 1 Expression on Ewing's Sarcoma, Enhancing T Cell Cytotoxicity.

Journal: Cells
Published: September 30, 2021

Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis.

Class I histone deacetylases (HDAC) critically contribute to Ewing sarcoma pathogenesis.

Journal: Journal of experimental & clinical cancer research : CR
Published: June 10, 2021

MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress.

MondoA drives malignancy in B-ALL through enhanced adaptation to metabolic stress.

Journal: Blood
Published: April 02, 2021

MHC Class I-Restricted TCR-Transgenic CD4+ T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo.

MHC Class I-Restricted TCR-Transgenic CD4+ T Cells Against STEAP1 Mediate Local Tumor Control of Ewing Sarcoma In Vivo.

Journal: Cells
Published: May 31, 2020

Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma.

Combined Inhibition of Epigenetic Readers and Transcription Initiation Targets the EWS-ETS Transcriptional Program in Ewing Sarcoma.

Journal: Cancers
Published: December 17, 2019

Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy.

Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy.

Journal: Oncotarget
Published: October 02, 2017
Showing 1-12 of 12

Last Updated: 09/26/2026